VBI Vaccines Was Notified That Its Common Shares Will Be Delisted From Nasdaq Effective As Of Opening Of Business On August 8, 2024; Does Not Intend To Appeal The Delisting Determination
Portfolio Pulse from Benzinga Newsdesk
VBI Vaccines (VBIV) has been notified that its common shares will be delisted from Nasdaq effective August 8, 2024. The company does not intend to appeal the delisting decision.

August 02, 2024 | 8:08 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
VBI Vaccines (VBIV) will be delisted from Nasdaq on August 8, 2024, and the company does not plan to appeal the decision. This could lead to a significant drop in stock price due to reduced liquidity and investor confidence.
The delisting from Nasdaq will likely result in a significant drop in VBIV's stock price due to reduced liquidity and investor confidence. The company's decision not to appeal the delisting further solidifies the negative outlook.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100